This inventor holds 2 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 3 EPO patents. Top assignee: Novartis Ag. Active years: 2009-2012.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2009-2012
Title: The Innovations of Jean-Louis Reber
Introduction
Jean-Louis Reber is a notable inventor based in Kembs, France. He has made significant contributions to the field of pharmaceuticals, particularly through his innovative patents. With a total of 2 patents, Reber's work focuses on compounds that have potential therapeutic applications.
Latest Patents
Reber's latest patents include the development of quinolinone derivatives and their pharmaceutical compositions. These compounds are designed to treat diseases mediated by the β-adrenoreceptor. The patent details compounds of formula I in salt or solvate form, which are useful in various medical applications. Another significant patent involves malic acid addition salts of terbinafine. This invention concerns the preparation of salts of the compound of formula I with malic acid, their corresponding pharmaceutical compositions, and their use as antimycotics.
Career Highlights
Throughout his career, Jean-Louis Reber has worked with prominent companies in the pharmaceutical industry. Notably, he has been associated with Novartis AG and Irm LLC. His experience in these organizations has contributed to his expertise in drug development and innovation.
Collaborations
Reber has collaborated with several professionals in his field, including Danielle Giron and Stefan Hirsch. These partnerships have likely enhanced his research and development efforts, leading to successful patent applications.
Conclusion
Jean-Louis Reber's contributions to pharmaceutical innovations demonstrate his commitment to advancing medical science. His patents reflect a deep understanding of complex compounds and their potential applications in treating various diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
